THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ELICERA THERAPEUTICS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.
Gothenburg, Sweden, June 10, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has received approval for admission to trading its share on the Nasdaq First North Growth Market. The first day for trading is Friday, June 11, 2021.
Trading in Elicera's securities
Elicera's share will be traded under the short name "ELIC" with ISIN-code SE0015382080 from Friday June 11, 2021.
Elicera's warrants TO1, which are included free of charge in the units that were issued, will be admitted to trading with the short name “ELIC TO1” and ISIN-code SE0015988233, after registration of the issue. A special press release will be issued before the first day of trading, which is planned for June 30, 2021.
Due to the listing on the Nasdaq First North Growth Market, Elicera has produced an additional document to be read together with the EU Growth Prospectus, which was prepared in connection with the recently completed public offering. These are available on Elicera's website,www.elicera.se.
G&W Fondkommission has been appointed the Company's Certified Adviser for the upcoming listing on the Nasdaq First North Growth Market (subject to approved application). E-mail: email@example.com, tel: +468-503 000 50.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer.
For more information, please visitwww.elicera.com
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Elicera. The invitation to interested persons to subscribe for shares and warrants in Elicera will only be made through the prospectus that Elicera published May 21, 2021. No action has been, or will be taken, by Elicera to allow an offer to the public in jurisdictions other than Sweden. This press release may not be published, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or the United States or any other jurisdiction where such action is subject in whole or in part to legal restrictions, or would require additional prospectuses, registration or other measures than what is required by Swedish law. The information contained in this press release may also not be transmitted or reproduced in ways that are contrary to such restrictions or would entail such requirements. Measures contrary to this instruction may constitute a breach of applicable securities laws. New shares and warrants subscribed for in the Offering have not been and will not be registered under the United States Securities Act of 1933 as amended (the "Securities Act") and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except under an applicable exemption from the registration requirements of the Securities Act. The Offer is also not addressed to persons domiciled in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or in any other jurisdiction where participation would require additional prospectuses, registration or other measures than those under Swedish law.